Alfentanil
As of the edition of 20 October 2026, Alfentanil is a small molecule: marketed, first approved in 1984 (FR); acts on OPRM1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1986
- Kind
- Small molecule
- Brand name
- Alfenta
- First approved
- 20 January 1984 (FR)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Rising Pharma; 2 holders in all
- Registered trials
- 34, 1 stopped early
- Disease areas
- Nervous system; Lungs and airways; Cancer; Heart and blood vessels; Infections; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Alfentanil.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| OPRM1 | Mu-type opioid receptor | P35372 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 20 | 16 | 1 | 0 |
| Phase 1 | 2 | 1 | 1 | 0 |
| Phase 4 | 12 | 6 | 4 | 1 |
| All trials | 34 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Rising Pharma | Acquired holder | 2023 to now |
| Johnson & Johnson | Originator | 1986 to 2023 |